A novel therapeutic approach for microsatellite instability (MSI) cancers, including those resistant to current immune checkpoint inhibitor (ICI) therapies, has emerged with the announcement of findings from a phase 1 trial for HRO761. This drug targets the Werner syndrome helicase (WRN) enzyme, exploiting a previously identified synthetic lethal vulnerability in these tumors. The development, highlighted by Jia Liu in a Nature Medicine article published on September 29, 2026, signals a new direction for treating a patient population with significant unmet needs.

The Mechanism of Synthetic Lethality: HRO761 and WRN Helicase

The concept of synthetic lethality is central to HRO761's mechanism. It refers to a situation where the simultaneous inactivation of two genes or proteins leads to cell death, while the inactivation of either one alone does not. In the context of MSI cancers, the Werner syndrome RecQ helicase (WRN) has been identified as a synthetic lethal target. This means that while normal cells can tolerate the loss of WRN function, MSI cancer cells, which already possess inherent defects in DNA mismatch repair pathways, become critically dependent on WRN to manage their genomic instability. Several genetic screens have consistently pointed to WRN as a selective dependency in MSI-H cancer cell lines, as noted in research published in *eLife Sciences*. HRO761, characterized by Stephane Ferretti and colleagues in *Nature*, is a potent, selective, and allosteric WRN inhibitor. Its mechanism involves binding at the interface of the D1 and D2 helicase domains of WRN, effectively locking the enzyme into an inactive conformation. This allosteric inhibition prevents WRN from performing its essential DNA repair functions, which are crucial for MSI cancer cells to survive their high rates of spontaneous mutations and DNA damage. The pharmacological inhibition by HRO761 precisely mirrors the effects observed when WRN is genetically suppressed. This leads to significant DNA damage accumulation and a selective inhibition of tumor cell growth specifically in MSI cells. Importantly, this effect is independent of the p53 tumor suppressor pathway, suggesting its potential efficacy even in tumors with p53 mutations. Further underscoring its selective action, HRO761 induces the degradation of WRN in MSI cells, a phenomenon not observed in microsatellite-stable (MSS) cells. This targeted degradation contributes to the drug's ability to exploit the unique vulnerabilities of MSI cancers while sparing healthy tissues.